12 Month Price Forecast For MIST
Distance to MIST Price Forecasts
MIST Price Momentum
๐ค Considering Milestone (MIST)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 16, 2025 5:15 AM UTC
MIST Analyst Ratings & Price Targets
Based on our analysis of 6 Wall Street analysts, MIST has a bullish consensus with a median price target of $7.00 (ranging from $2.00 to $25.00). Currently trading at $2.27, the median forecast implies a 208.4% upside. This outlook is supported by 3 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 1,001.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MIST Analyst Consensus
MIST Price Target Range
Latest MIST Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MIST.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 27, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
Oct 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
Aug 22, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
Aug 22, 2024 | Rodman & Renshaw | Brandon Folkes | Buy | Initiates | $9.00 |
Jul 1, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
May 30, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
May 16, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
Mar 22, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
Mar 5, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $5.00 |
Feb 26, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
Dec 27, 2023 | TD Cowen | Outperform | Maintains | $9.00 | |
Aug 14, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
Jun 20, 2023 | Jefferies | Hold | Downgrade | $0.00 | |
May 23, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
May 15, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
Apr 12, 2023 | Oppenheimer | Leland Gershell | Outperform | Maintains | $13.00 |
Mar 30, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
Mar 9, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $25.00 |
Nov 14, 2022 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $25.00 |
Apr 22, 2022 | Piper Sandler | Edward Tenthoff | Overweight | Upgrade | $10.00 |
Stocks Similar to Milestone Pharmaceuticals Inc.
The following stocks are similar to Milestone based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Milestone Pharmaceuticals Inc. (MIST) Financial Data
Milestone Pharmaceuticals Inc. has a market capitalization of $122.12M with a P/E ratio of -1.6x. The company generates $1.00M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -5,713.1% and return on equity of -162.9%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Milestone Pharmaceuticals Inc. (MIST) Company Overview
About Milestone Pharmaceuticals Inc.
Develops cardiovascular medicines.
Milestone Pharmaceuticals focuses on developing innovative cardiovascular drugs, particularly etripamil, which is currently undergoing clinical trials. The company generates revenue through licensing and collaboration agreements with partners like Ji Xing Pharmaceuticals and research institutions for the development and commercialization of its products.
Founded in 2003 and headquartered in Montrรฉal, Canada, Milestone is targeting significant cardiovascular conditions, which could lead to substantial market opportunities pending successful clinical trial outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
47
CEO
Mr. Joseph G. Oliveto M.B.A.
Country
Canada
IPO Year
N/A
Website
www.milestonepharma.comMilestone Pharmaceuticals Inc. (MIST) Latest News & Analysis
Milestone Pharmaceuticals Inc. will host an investor event in New York on February 25, 2025, to discuss its Commercial Launch Plan for cardiovascular medicines.
Milestone Pharmaceuticals' upcoming investor event may signal strategic developments in its product launch, potentially impacting stock performance and investor sentiment.
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC
18 days agoThe PDUFA date for CARDAMYSTโข (etripamil) nasal spray, indicated for Paroxysmal Supraventricular Tachycardia (PSVT), is set for March 27, 2025.
The PDUFA date indicates a critical timeline for regulatory approval, impacting potential revenue and stock performance for the company developing CARDAMYSTโข.
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 month agoMilestone Pharmaceuticals granted 113,000 stock options to three new employees under its 2021 Inducement Plan, approved by the Compensation Committee and Board of Directors.
The granting of equity awards indicates Milestone's commitment to incentivizing talent, which can enhance company performance and drive shareholder value.
Milestone Pharmaceuticals Inc. (MIST) has shown a technical signal of a "golden cross," with its 50-day moving average surpassing the 200-day moving average, indicating potential investor interest.
Milestone Pharmaceuticals' golden cross indicates bullish momentum, often signaling potential price increases, attracting technical traders and enhancing investor interest.
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
3 months agoThe FDA is reviewing the NDA for CARDAMYSTโข for the treatment of PSVT, with a PDUFA date set for March 27, 2025.
The FDA's review and upcoming decision on CARDAMYSTโข could significantly impact the company's stock price and future revenue, influencing investor sentiment and market positioning.
Milestone Pharmaceuticals' partner, Ji Xing Pharmaceuticals, reported positive results from a trial in China for etripamil nasal spray in treating paroxysmal supraventricular tachycardia (PSVT).
Positive trial results for etripamil nasal spray enhance Milestone Pharmaceuticals' market potential, likely boosting investor confidence and interest in the company's stock.
Frequently Asked Questions About MIST Stock
What is Milestone Pharmaceuticals Inc.'s (MIST) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Milestone Pharmaceuticals Inc. (MIST) has a median price target of $7.00. The highest price target is $25.00 and the lowest is $2.00.
Is MIST stock a good investment in 2025?
According to current analyst ratings, MIST has 3 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.27. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for MIST stock?
Wall Street analysts predict MIST stock could reach $7.00 in the next 12 months. This represents a 208.4% increase from the current price of $2.27. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Milestone Pharmaceuticals Inc.'s business model?
Milestone Pharmaceuticals focuses on developing innovative cardiovascular drugs, particularly etripamil, which is currently undergoing clinical trials. The company generates revenue through licensing and collaboration agreements with partners like Ji Xing Pharmaceuticals and research institutions for the development and commercialization of its products.
What is the highest forecasted price for MIST Milestone Pharmaceuticals Inc.?
The highest price target for MIST is $25.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 1,001.3% increase from the current price of $2.27.
What is the lowest forecasted price for MIST Milestone Pharmaceuticals Inc.?
The lowest price target for MIST is $2.00 from at , which represents a -11.9% decrease from the current price of $2.27.
What is the overall MIST consensus from analysts for Milestone Pharmaceuticals Inc.?
The overall analyst consensus for MIST is bullish. Out of 6 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are MIST stock price projections?
Stock price projections, including those for Milestone Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.